Medicare AdvantageCoverageLow impact
MA07.044b, Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders
Independence Blue Cross·Pulmonology, Allergy & Immunology·Medical Policy
Effective date
Jan 22, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA07.044b for measurement of exhaled nitric oxide and breath condensate in asthma and respiratory disorder diagnosis has been reissued. This policy update affects billing and coverage criteria for specialized respiratory diagnostic testing procedures used primarily in pulmonology practices.
Action Required
By January 22, 2025: Billing team should review the updated policy MA07.044b to understand current coverage criteria for exhaled nitric oxide and breath condensate testing procedures. Verify that any claims for these specialized respiratory diagnostic tests meet the updated Medicare Advantage requirements to avoid denials.